Skip to main content

A hematology clinical trial - ALC10

Comparing the usual treatment of older adults with acute myeloid leukemia with two new treatment approaches
Disease Site
Hematologic Clinical Trials
Trial Code
ALC.10 (MM1OA-EA02) ǀ NCT06317649
Trial Status
Open to patient enrollment

What is the purpose of this trial?

The purpose of this study is to compare the usual treatment for FLT3 mutated acute myeloid leukemia (AML) with a new drug that has two different treatment schedules.

This trial is part of a larger platform study called myeloMATCH – https://www.ctg.queensu.ca/patients/hematology-clinical-trial-alc7.

Why is this trial important?

The treatments being studied are new combinations being developed for the treatment of AML. The new treatments have been studied in a few people and seem promising, but it is not clear if they can offer better results than standard treatment.

Who can participate in this study?

This trial is for:

  • people with previously untreated AML with specific mutations
  • ≥ 60 years of age or adults ˂ 60 who cannot be treated with intensive chemotherapy

This trial is not for people:

  • receiving any other investigational treatment
  • with acute promyelocytic leukemia and some other specific types of AML
  • who are pregnant and/or breastfeeding
What are the risks?
  • If you choose to take part in this study, there is a risk that the study approach may not be as good as the standard treatment. There is also a risk that you could have side effects from the study drugs. Some of the most common side effects that the study doctors know about are: decrease in the number of red or white blood cells or platelets, diarrhea, nausea and vomiting, and tiredness or fever. You will find details of all side effects in the consent document.
What can I expect?
  • If you choose to take part in this study, you will be randomly placed in one of three groups. You will receive either the usual treatment, the new drug for 28 days with the usual treatment, or the new drug for 14 days with the usual treatment.
  • In this study, you will also be asked to complete diaries at different times, to record the number of pills you take.

How can I find out more or join the study?

Talk to your cancer doctor if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you.

Before you join this study, you will be asked to review an Informed Consent document which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your standard medical care.

The ALC.10 study is currently enrolling patients at cancer centres in Canada. For a full list of participating cancer centres please visit https://clinicaltrials.gov/study/NCT06317649

Use this trial information for your conversation with your health care team

Participating centres

Information coming soon.